Enfusion (ENFN) Financials

$10.85 +0.05 (+0.45%)

Closing price 04/17/2025

Extended Trading

$10.85 0.00 (0.00%)

As of 04/17/2025 04:24 PM Eastern

Annual Income Statements for Enfusion

This table shows Enfusion's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	13	4.06	-158	-7.65	6.03	2.82
Consolidated Net Income / (Loss)	13	4.06	-282	-13	9.25	3.92
Net Income / (Loss) Continuing Operations	13	4.06	-282	-13	9.25	3.92
Total Pre-Tax Income	13	4.49	-282	-12	11	7.39
Total Operating Income	14	6.07	-276	-12	12	6.16
Total Gross Profit	42	58	80	103	117	137
Total Revenue	59	80	112	150	175	202
Operating Revenue	59	80	112	150	175	202
Total Cost of Revenue	17	21	32	47	58	65
Operating Cost of Revenue	17	21	32	47	58	65
Total Operating Expenses	28	52	356	115	105	131
Selling, General & Admin Expense	17	36	151	69	65	79
Marketing Expense	7.43	9.93	52	29	20	25
Research & Development Expense	4.15	6.32	153	17	20	27
Total Other Income / (Expense), net	-0.73	-1.58	-5.78	-0.23	-0.46	1.23
Interest & Investment Income	-	-1.66	-4.59	0.41	1.64	1.69
Other Income / (Expense), net	-0.00	0.08	-1.19	-0.64	-2.11	-0.46
Income Tax Expense	0.49	0.43	0.58	1.07	2.23	3.47
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	0.00	-124	-5.61	3.23	1.09
Basic Earnings per Share	$0.00	$0.00	($2.26)	($0.10)	$0.07	$0.03
Weighted Average Basic Shares Outstanding	0.00	0.00	83.05M	85.39M	88.20M	92.05M
Diluted Earnings per Share	$0.00	$0.00	($2.26)	($0.10)	$0.07	$0.03
Weighted Average Diluted Shares Outstanding	0.00	0.00	83.05M	85.39M	129.43M	129.55M
Weighted Average Basic & Diluted Shares Outstanding	-	-	113.05M	230.54M	256.14M	258.00M

This table shows Enfusion's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	1.54	0.49	2.95	0.63	1.83	0.62	-0.54	1.83	1.42	0.12
Consolidated Net Income / (Loss)	2.60	0.79	4.69	1.00	2.66	0.90	-0.76	2.55	1.96	0.17
Net Income / (Loss) Continuing Operations	2.60	0.79	4.69	1.00	2.66	0.90	-0.76	2.55	1.96	0.17
Total Pre-Tax Income	2.89	1.21	5.09	1.19	3.03	2.18	-0.88	2.95	2.86	2.46
Total Operating Income	2.94	1.37	4.68	2.45	2.69	2.13	-1.11	2.70	2.98	1.58
Total Gross Profit	27	27	28	29	30	31	32	33	35	37
Total Revenue	39	41	41	43	44	46	48	49	51	53
Operating Revenue	39	41	41	43	44	46	48	49	51	53
Total Cost of Revenue	12	13	13	14	15	16	16	16	16	16
Operating Cost of Revenue	12	13	13	14	15	16	16	16	16	16
Total Operating Expenses	24	26	23	26	27	29	33	31	32	35
Selling, General & Admin Expense	13	15	14	16	17	17	20	19	19	21
Marketing Expense	7.28	6.00	4.09	5.28	5.50	5.55	6.22	6.02	6.22	6.57
Research & Development Expense	3.86	4.78	4.43	4.46	4.94	6.06	6.55	6.10	6.84	7.24
Total Other Income / (Expense), net	-0.06	-0.17	0.41	-1.26	0.34	0.05	0.24	0.25	-0.12	0.87
Interest & Investment Income	-	-	0.49	0.46	0.25	0.44	0.32	0.36	0.49	0.53
Other Income / (Expense), net	-0.06	-0.58	-0.08	-1.72	0.17	-0.47	-0.08	-0.11	-0.61	0.34
Income Tax Expense	0.29	0.42	0.40	0.19	0.37	1.28	-0.12	0.40	0.90	2.29
Net Income / (Loss) Attributable to Noncontrolling Interest	1.06	0.29	1.75	0.37	0.83	0.28	-0.22	0.72	0.54	0.05
Weighted Average Basic Shares Outstanding	85.16M	85.39M	88.86M	88.31M	87.74M	88.20M	89.51M	91.48M	92.90M	92.05M
Weighted Average Diluted Shares Outstanding	131.76M	85.39M	132.35M	129.86M	127.84M	129.43M	89.51M	128.85M	128.98M	129.55M
Weighted Average Basic & Diluted Shares Outstanding	228.11M	230.54M	232.57M	246.86M	254.96M	256.14M	256.22M	256.82M	257.14M	258.00M

This table details how cash moves in and out of Enfusion's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	0.25	8.04	50	-1.82	-27	19
Net Cash From Operating Activities	12	1.67	-0.32	14	26	35
Net Cash From Continuing Operating Activities	12	1.67	-0.32	14	26	35
Net Income / (Loss) Continuing Operations	13	4.06	-282	-13	9.25	3.92
Consolidated Net Income / (Loss)	13	4.06	-282	-13	9.25	3.92
Depreciation Expense	1.16	2.29	3.98	6.34	9.99	12
Amortization Expense	0.02	0.06	0.22	0.03	0.09	0.23
Non-Cash Adjustments To Reconcile Net Income	0.27	1.01	292	32	16	27
Changes in Operating Assets and Liabilities, net	-1.80	-5.76	-15	-11	-9.44	-7.87
Net Cash From Investing Activities	-4.43	-5.07	-8.01	-7.93	-9.67	-14
Net Cash From Continuing Investing Activities	-4.43	-5.07	-8.01	-7.93	-9.67	-14
Purchase of Property, Plant & Equipment	-4.43	-5.07	-8.01	-7.93	-9.67	-11
Other Investing Activities, net	-	-	-	0.00	0.00	-3.00
Net Cash From Financing Activities	-7.54	12	59	-7.96	-43	-1.40
Net Cash From Continuing Financing Activities	-7.54	12	59	-7.96	-43	-1.40
Repayment of Debt	-2.09	-2.27	-100	0.00	-1.46	0.00
Payment of Dividends	-35	-76	-3.28	0.00	0.00	-0.14
Issuance of Common Equity	57	93	261	0.00	17	0.00
Other Financing Activities, net	-57	-77	-11	-7.96	-59	-1.27
Effect of Exchange Rate Changes	-0.09	-0.12	-0.09	-0.09	0.18	-0.51
Cash Income Taxes Paid	-	0.26	0.41	1.58	1.84	2.05

This table details how cash moves in and out of Enfusion's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	6.98	-1.00	-7.95	-27	3.88	3.95	-2.71	1.55	14	6.18
Net Cash From Operating Activities	7.84	7.52	0.92	6.02	12	6.59	1.53	7.31	16	9.67
Net Cash From Continuing Operating Activities	7.84	7.52	0.92	6.02	12	6.59	1.53	7.31	16	9.67
Net Income / (Loss) Continuing Operations	2.60	0.79	4.69	1.00	2.66	0.90	-0.76	2.55	1.96	0.17
Consolidated Net Income / (Loss)	2.60	0.79	4.69	1.00	2.66	0.90	-0.76	2.55	1.96	0.17
Depreciation Expense	1.70	1.69	1.87	2.08	2.52	3.52	2.67	2.87	2.96	3.25
Amortization Expense	0.01	0.01	0.01	0.01	0.00	0.08	0.06	0.06	0.06	0.06
Non-Cash Adjustments To Reconcile Net Income	2.51	5.87	0.87	4.50	5.38	4.98	8.63	6.55	5.60	5.88
Changes in Operating Assets and Liabilities, net	1.03	-0.84	-6.52	-1.57	1.54	-2.89	-9.06	-4.71	5.59	0.32
Net Cash From Investing Activities	-0.92	-1.75	-2.55	-2.22	-2.61	-2.30	-2.75	-5.71	-2.78	-2.66
Net Cash From Continuing Investing Activities	-0.92	-1.75	-2.55	-2.22	-2.61	-2.30	-2.75	-5.71	-2.78	-2.66
Purchase of Property, Plant & Equipment	-0.92	-1.75	-2.55	-2.22	-2.61	-2.30	-2.75	-2.71	-2.78	-2.66
Effect of Exchange Rate Changes	0.08	0.27	0.03	0.22	-0.31	0.24	-0.12	-0.04	0.48	-0.83
Cash Income Taxes Paid	0.72	0.53	0.21	0.13	0.26	1.25	0.37	0.17	0.31	1.21

This table presents Enfusion's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	39	106	124	109	143
Total Current Assets	29	90	97	70	94
Cash & Equivalents	14	64	63	36	54
Accounts Receivable	12	18	26	28	32
Prepaid Expenses	2.79	6.03	6.11	5.01	5.34
Other Current Assets	-	1.06	2.30	1.17	1.71
Plant, Property, & Equipment, net	8.78	13	16	18	21
Total Noncurrent Assets	1.40	3.36	11	21	29
Noncurrent Note & Lease Receivables	-	-	-	0.00	3.00
Other Noncurrent Operating Assets	1.40	3.36	11	21	26
Total Liabilities & Shareholders' Equity	39	106	124	109	143
Total Liabilities	107	8.64	20	31	44
Total Current Liabilities	11	8.11	17	20	27
Accounts Payable	0.48	2.53	1.69	2.21	0.87
Accrued Expenses	7.67	5.58	12	14	20
Other Current Liabilities	-	0.00	4.03	4.26	6.08
Total Noncurrent Liabilities	96	0.54	2.96	11	16
Capital Lease Obligations	-	-	2.96	11	14
Other Noncurrent Operating Liabilities	0.43	0.54	-	0.00	2.15
Commitments & Contingencies	0.00	-	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-234	97	103	77	100
Total Preferred & Common Equity	-234	55	65	54	73
Preferred Stock	0.00	-	0.00	0.00	0.00
Total Common Equity	-234	55	65	54	73
Common Stock	-233	227	244	227	244
Retained Earnings	0.00	-171	-179	-173	-170
Accumulated Other Comprehensive Income / (Loss)	-0.21	-0.33	-0.50	-0.41	-0.73
Noncontrolling Interest	0.00	42	38	24	26

This table presents Enfusion's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	116	121	94	102	111	120	135
Total Current Assets	96	87	60	62	71	74	85
Cash & Equivalents	64	55	28	32	33	34	48
Accounts Receivable	29	24	25	25	31	34	32
Prepaid Expenses	2.61	5.60	4.97	4.08	5.42	4.48	3.58
Other Current Assets	0.89	2.09	1.72	1.46	1.68	1.57	1.39
Plant, Property, & Equipment, net	15	17	18	18	19	20	21
Total Noncurrent Assets	4.15	18	17	22	21	26	29
Noncurrent Note & Lease Receivables	-	-	-	-	-	3.00	3.00
Other Noncurrent Operating Assets	4.15	18	17	22	21	23	26
Total Liabilities & Shareholders' Equity	116	121	94	102	111	120	135
Total Liabilities	12	22	22	28	28	31	39
Total Current Liabilities	12	14	14	16	17	18	24
Accounts Payable	1.19	1.29	0.87	1.34	3.36	0.82	1.18
Accrued Expenses	11	7.40	8.13	11	9.51	12	16
Other Current Liabilities	-	5.01	4.76	4.40	4.53	5.19	5.94
Total Noncurrent Liabilities	0.44	8.64	8.05	12	11	13	15
Capital Lease Obligations	-	-	8.05	12	-	13	15
Commitments & Contingencies	-	-	-	-	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	103	99	72	73	83	89	96
Total Preferred & Common Equity	61	64	48	51	58	64	70
Preferred Stock	-	-	0.00	0.00	0.00	0.00	0.00
Total Common Equity	61	64	48	51	58	64	70
Common Stock	241	240	224	225	232	236	240
Retained Earnings	-179	-176	-175	-174	-173	-172	-170
Accumulated Other Comprehensive Income / (Loss)	-0.67	-0.47	-0.38	-0.55	-0.48	-0.51	-0.20
Noncontrolling Interest	42	35	24	23	25	25	26

This table displays calculated financial ratios and metrics derived from Enfusion's official financial filings.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	34.79%	40.39%	34.60%	16.09%	15.51%
EBITDA Growth	0.00%	-43.46%	-3,307.62%	97.72%	419.67%	-11.23%
EBIT Growth	0.00%	-55.60%	-4,600.80%	95.45%	178.11%	-42.13%
NOPAT Growth	0.00%	-58.90%	-3,618.44%	95.66%	214.95%	-66.12%
Net Income Growth	0.00%	-67.91%	-7,050.06%	95.30%	169.77%	-57.69%
EPS Growth	0.00%	0.00%	0.00%	95.58%	170.00%	-57.14%
Operating Cash Flow Growth	0.00%	-86.47%	-119.10%	4,551.57%	81.08%	35.30%
Free Cash Flow Firm Growth	0.00%	0.00%	-1,789.73%	90.86%	102.22%	-798.55%
Invested Capital Growth	0.00%	0.00%	99.48%	32.60%	20.98%	11.75%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	6.12%	3.54%	3.31%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	97.93%	16.13%	-0.15%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	95.90%	9.74%	4.74%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	96.09%	-1.05%	-25.51%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	95.69%	1.23%	-15.68%
EPS Q/Q Growth	0.00%	0.00%	0.00%	95.78%	-12.50%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	94.13%	1,620.05%	-3.52%	9.77%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	109.77%	40.24%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	10.68%	-1.22%	-5.99%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	71.27%	73.16%	71.49%	68.67%	66.97%	67.82%
EBITDA Margin	25.49%	10.69%	-244.29%	-4.15%	11.41%	8.77%
Operating Margin	23.50%	7.63%	-246.99%	-7.96%	6.85%	3.05%
EBIT Margin	23.49%	7.74%	-248.05%	-8.38%	5.64%	2.83%
Profit (Net Income) Margin	21.44%	5.10%	-252.68%	-8.82%	5.30%	1.94%
Tax Burden Percent	96.30%	90.36%	100.21%	108.81%	80.57%	52.98%
Interest Burden Percent	94.78%	73.00%	101.66%	96.72%	116.67%	129.72%
Effective Tax Rate	3.70%	9.64%	0.00%	0.00%	19.43%	47.02%
Return on Invested Capital (ROIC)	0.00%	66.21%	-777.81%	-21.77%	19.87%	5.81%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	62.83%	-1,657.61%	-13.88%	20.76%	3.78%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-78.14%	-1,142.40%	8.57%	-9.64%	-1.38%
Return on Equity (ROE)	0.00%	-11.94%	-1,920.21%	-13.20%	10.23%	4.42%
Cash Return on Invested Capital (CROIC)	0.00%	-133.79%	-844.25%	-49.80%	0.88%	-5.30%
Operating Return on Assets (OROA)	0.00%	15.74%	-381.68%	-10.96%	8.46%	4.52%
Return on Assets (ROA)	0.00%	10.39%	-388.81%	-11.54%	7.95%	3.10%
Return on Common Equity (ROCE)	0.00%	-40.97%	11,644.12%	-7.91%	6.71%	3.17%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-1.74%	-510.42%	-20.40%	17.24%	5.35%
Net Operating Profit after Tax (NOPAT)	13	5.49	-193	-8.37	9.63	3.26
NOPAT Margin	22.63%	6.90%	-172.89%	-5.57%	5.52%	1.62%
Net Nonoperating Expense Percent (NNEP)	0.00%	3.37%	879.79%	-7.89%	-0.89%	2.02%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-7.87%	10.86%	2.87%
Cost of Revenue to Revenue	28.73%	26.84%	28.51%	31.33%	33.03%	32.18%
SG&A Expenses to Revenue	28.17%	45.11%	134.84%	45.74%	37.03%	39.10%
R&D to Revenue	7.02%	7.94%	137.33%	11.42%	11.40%	13.26%
Operating Expenses to Revenue	47.77%	65.52%	318.48%	76.63%	60.13%	64.77%
Earnings before Interest and Taxes (EBIT)	14	6.16	-277	-13	9.84	5.70
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	15	8.51	-273	-6.23	20	18
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	42.81	33.93	46.08	36.17
Price to Tangible Book Value (P/TBV)	0.00	0.00	42.81	33.93	46.08	36.17
Price to Revenue (P/Rev)	5.40	4.01	21.19	14.67	14.17	13.14
Price to Earnings (P/E)	25.19	78.49	0.00	0.00	410.47	938.21
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.97%	1.27%	0.00%	0.00%	0.24%	0.11%
Enterprise Value to Invested Capital (EV/IC)	0.00	34.31	70.90	49.81	46.60	44.43
Enterprise Value to Revenue (EV/Rev)	0.00	7.15	21.00	14.53	14.17	13.07
Enterprise Value to EBITDA (EV/EBITDA)	0.00	66.87	0.00	0.00	124.11	148.98
Enterprise Value to EBIT (EV/EBIT)	0.00	92.41	0.00	0.00	251.19	462.54
Enterprise Value to NOPAT (EV/NOPAT)	0.00	103.65	0.00	0.00	256.83	807.88
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	341.68	0.00	154.33	96.45	75.97
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	5,805.86	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	-1.45	0.00	0.03	0.14	0.14
Long-Term Debt to Equity	0.00	-1.41	0.00	0.03	0.14	0.14
Financial Leverage	0.00	-1.24	0.69	-0.62	-0.46	-0.37
Leverage Ratio	0.00	-0.57	4.94	1.14	1.29	1.42
Compound Leverage Factor	0.00	-0.42	5.02	1.11	1.50	1.85
Debt to Total Capital	0.00%	322.96%	0.00%	2.78%	12.61%	12.51%
Short-Term Debt to Total Capital	0.00%	8.19%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	314.76%	0.00%	2.78%	12.61%	12.51%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	542.33%	43.25%	36.12%	26.86%	23.13%
Common Equity to Total Capital	0.00%	-765.29%	56.75%	61.10%	60.53%	64.36%
Debt to EBITDA	0.00	11.59	0.00	-0.47	0.56	0.81
Net Debt to EBITDA	0.00	9.95	0.00	9.56	-1.23	-2.28
Long-Term Debt to EBITDA	0.00	11.29	0.00	-0.47	0.56	0.81
Debt to NOPAT	0.00	17.96	0.00	-0.35	1.16	4.37
Net Debt to NOPAT	0.00	15.42	0.00	7.11	-2.54	-12.34
Long-Term Debt to NOPAT	0.00	17.50	0.00	-0.35	1.16	4.37
Altman Z-Score	0.00	4.90	155.42	64.70	47.34	36.78
Noncontrolling Interest Sharing Ratio	0.00%	-243.25%	706.40%	40.11%	34.41%	28.32%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	0.00	2.71	11.06	5.57	3.44	3.42
Quick Ratio	0.00	2.45	10.19	5.09	3.14	3.16
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-11	-210	-19	0.43	-2.97
Operating Cash Flow to CapEx	277.85%	32.85%	-3.97%	178.49%	265.06%	318.42%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	17.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	10.88	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	2.04	1.54	1.31	1.50	1.60
Accounts Receivable Turnover	0.00	6.53	7.35	6.82	6.47	6.71
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	9.06	10.23	10.44	10.24	10.27
Accounts Payable Turnover	0.00	44.13	21.15	22.36	29.58	42.14
Days Sales Outstanding (DSO)	0.00	55.88	49.67	53.50	56.38	54.36
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	8.27	17.26	16.32	12.34	8.66
Cash Conversion Cycle (CCC)	0.00	47.60	32.41	37.18	44.05	45.70
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	0.00	17	33	44	53	59
Invested Capital Turnover	0.00	9.60	4.50	3.91	3.60	3.59
Increase / (Decrease) in Invested Capital	0.00	17	16	11	9.20	6.24
Enterprise Value (EV)	0.00	569	2,345	2,185	2,472	2,635
Market Capitalization	319	319	2,367	2,206	2,473	2,649
Book Value per Share	$0.00	($12.46)	$0.49	$0.29	$0.21	$0.28
Tangible Book Value per Share	$0.00	($12.46)	$0.49	$0.29	$0.21	$0.28
Total Capital	0.00	31	97	106	89	114
Total Debt	0.00	99	0.00	2.96	11	14
Total Long-Term Debt	0.00	96	0.00	2.96	11	14
Net Debt	0.00	85	-64	-60	-24	-40
Capital Expenditures (CapEx)	4.43	5.07	8.01	7.93	9.67	11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	6.82	17	17	14	12
Debt-free Net Working Capital (DFNWC)	0.00	21	82	79	50	66
Net Working Capital (NWC)	0.00	18	82	79	50	66
Net Nonoperating Expense (NNE)	0.70	1.43	89	4.89	0.37	-0.65
Net Nonoperating Obligations (NNO)	0.00	85	-64	-60	-24	-40
Total Depreciation and Amortization (D&A)	1.18	2.35	4.20	6.37	10	12
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	8.58%	15.40%	11.23%	7.99%	5.81%
Debt-free Net Working Capital to Revenue	0.00%	26.09%	73.03%	52.83%	28.39%	32.83%
Net Working Capital to Revenue	0.00%	22.95%	73.03%	52.83%	28.39%	32.83%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($2.26)	($0.10)	$0.07	$0.03
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	83.05M	85.39M	88.20M	92.05M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($2.26)	($0.10)	$0.07	$0.03
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	83.05M	85.39M	129.43M	129.55M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	113.05M	230.54M	256.14M	258.00M
Normalized Net Operating Profit after Tax (NOPAT)	13	5.49	-193	-8.37	9.63	3.26
Normalized NOPAT Margin	22.63%	6.90%	-172.89%	-5.57%	5.52%	1.62%
Pre Tax Income Margin	22.26%	5.65%	-252.16%	-8.11%	6.58%	3.67%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	19.15	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	18.45	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	13.03	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	12.33	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	276.64%	1,863.41%	-1.16%	0.00%	0.00%	3.47%
Augmented Payout Ratio	276.64%	1,863.41%	-32.29%	0.00%	0.00%	3.47%

This table displays calculated financial ratios and metrics derived from Enfusion's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	34.79%	27.20%	20.01%	16.92%	13.30%	14.73%	17.28%	15.76%	15.35%	13.88%
EBITDA Growth	-23.41%	100.85%	158.69%	223.16%	17.21%	111.12%	-76.24%	96.34%	0.24%	-0.51%
EBIT Growth	-41.50%	100.27%	137.16%	118.54%	-1.07%	110.21%	-125.99%	258.01%	-16.82%	15.48%
NOPAT Growth	-43.46%	100.44%	149.83%	175.28%	-10.77%	-1.72%	-118.06%	13.46%	-13.71%	-87.42%
Net Income Growth	-21.11%	100.27%	137.48%	124.19%	2.42%	14.21%	-116.21%	155.21%	-26.46%	-80.89%
EPS Growth	0.00%	100.44%	140.00%	133.33%	0.00%	0.00%	-125.00%	100.00%	0.00%	0.00%
Operating Cash Flow Growth	439.63%	229.40%	122.55%	108.24%	54.37%	-12.43%	65.91%	21.54%	33.50%	46.87%
Free Cash Flow Firm Growth	68.99%	0.00%	100.55%	84.30%	-53.38%	15.84%	-2,309.13%	-78.86%	37.60%	26.38%
Invested Capital Growth	35.09%	32.60%	9.99%	21.45%	35.55%	20.98%	11.64%	29.03%	17.42%	11.75%
Revenue Q/Q Growth	7.15%	3.49%	1.12%	4.27%	3.83%	4.80%	3.37%	2.92%	3.46%	3.46%
EBITDA Q/Q Growth	300.96%	-45.75%	159.92%	-56.54%	91.25%	-2.29%	-69.27%	259.10%	-2.35%	-3.02%
EBIT Q/Q Growth	173.86%	-72.51%	479.82%	-84.25%	294.20%	-41.59%	-184.45%	316.90%	-8.41%	-18.91%
NOPAT Q/Q Growth	196.86%	-66.15%	381.33%	-52.30%	14.81%	-62.72%	-188.43%	399.75%	-12.69%	-94.56%
Net Income Q/Q Growth	162.98%	-69.67%	495.69%	-78.74%	166.63%	-66.18%	-184.56%	434.69%	-23.16%	-91.21%
EPS Q/Q Growth	166.67%	-50.00%	300.00%	-75.00%	100.00%	0.00%	0.00%	300.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	171.35%	-4.09%	-87.71%	551.30%	101.16%	-45.60%	-76.72%	377.10%	120.97%	-40.15%
Free Cash Flow Firm Q/Q Growth	83.37%	-29.31%	102.73%	-2,773.85%	-62.42%	29.04%	28.32%	-116.49%	43.33%	16.29%
Invested Capital Q/Q Growth	-8.37%	10.68%	1.57%	17.91%	2.27%	-1.22%	-6.27%	36.27%	-6.94%	-5.99%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	69.42%	67.18%	67.53%	66.74%	67.29%	66.39%	66.34%	67.72%	68.06%	69.02%
EBITDA Margin	11.72%	6.15%	15.80%	6.58%	12.13%	11.31%	3.20%	11.17%	10.54%	9.88%
Operating Margin	7.51%	3.39%	11.42%	5.73%	6.06%	4.59%	-2.32%	5.47%	5.83%	2.99%
EBIT Margin	7.37%	1.96%	11.22%	1.69%	6.43%	3.59%	-2.49%	5.24%	4.64%	3.64%
Profit (Net Income) Margin	6.64%	1.94%	11.46%	2.34%	6.00%	1.94%	-1.58%	5.15%	3.82%	0.32%
Tax Burden Percent	90.05%	65.34%	92.22%	84.15%	87.88%	41.28%	86.67%	86.40%	68.40%	7.00%
Interest Burden Percent	100.00%	152.08%	110.70%	163.81%	106.10%	130.77%	73.47%	113.73%	120.51%	127.69%
Effective Tax Rate	9.95%	34.66%	7.78%	15.85%	12.12%	58.72%	0.00%	13.60%	31.60%	93.00%
Return on Invested Capital (ROIC)	27.80%	8.65%	38.93%	16.44%	19.24%	6.83%	-6.25%	14.79%	13.32%	0.75%
ROIC Less NNEP Spread (ROIC-NNEP)	27.82%	8.82%	38.24%	19.22%	18.52%	6.78%	-6.29%	13.76%	13.63%	0.56%
Return on Net Nonoperating Assets (RNNOA)	-23.49%	-5.44%	-21.64%	-8.52%	-8.72%	-3.15%	3.03%	-3.52%	-4.24%	-0.21%
Return on Equity (ROE)	4.31%	3.20%	17.29%	7.92%	10.52%	3.68%	-3.22%	11.27%	9.08%	0.55%
Cash Return on Invested Capital (CROIC)	0.00%	-49.80%	-0.54%	1.54%	-9.34%	0.88%	-2.01%	-17.52%	-8.53%	-5.30%
Operating Return on Assets (OROA)	12.64%	2.56%	15.58%	2.71%	9.98%	5.38%	-3.89%	9.22%	7.65%	5.81%
Return on Assets (ROA)	11.38%	2.54%	15.90%	3.74%	9.31%	2.90%	-2.47%	9.06%	6.31%	0.52%
Return on Common Equity (ROCE)	0.59%	1.92%	10.47%	4.94%	6.67%	2.41%	-2.16%	7.83%	6.47%	0.39%
Return on Equity Simple (ROE_SIMPLE)	-503.76%	0.00%	6.21%	18.86%	18.02%	0.00%	6.54%	8.32%	6.64%	0.00%
Net Operating Profit after Tax (NOPAT)	2.65	0.90	4.31	2.06	2.36	0.88	-0.78	2.34	2.04	0.11
NOPAT Margin	6.76%	2.21%	10.53%	4.82%	5.33%	1.90%	-1.62%	4.72%	3.99%	0.21%
Net Nonoperating Expense Percent (NNEP)	-0.03%	-0.18%	0.68%	-2.78%	0.72%	0.05%	0.04%	1.02%	-0.31%	0.19%
Return On Investment Capital (ROIC_SIMPLE)	-	0.84%	-	-	-	0.99%	-	-	-	0.10%
Cost of Revenue to Revenue	30.58%	32.82%	32.47%	33.26%	32.71%	33.61%	33.66%	32.28%	31.94%	30.98%
SG&A Expenses to Revenue	33.44%	37.20%	35.33%	38.22%	37.70%	36.82%	42.09%	37.76%	36.71%	39.95%
R&D to Revenue	9.87%	11.79%	10.82%	10.45%	11.13%	13.04%	13.63%	12.33%	13.37%	13.67%
Operating Expenses to Revenue	61.90%	63.80%	56.11%	61.02%	61.23%	61.80%	68.66%	62.26%	62.24%	66.03%
Earnings before Interest and Taxes (EBIT)	2.89	0.79	4.60	0.72	2.85	1.67	-1.20	2.59	2.37	1.93
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4.59	2.49	6.47	2.81	5.38	5.26	1.54	5.52	5.39	5.23
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	45.65	33.93	38.00	54.22	43.65	46.08	40.81	33.95	34.86	36.17
Price to Tangible Book Value (P/TBV)	45.65	33.93	38.00	54.22	43.65	46.08	40.81	33.95	34.86	36.17
Price to Revenue (P/Rev)	19.70	14.67	15.40	15.97	13.14	14.17	13.05	11.59	12.49	13.14
Price to Earnings (P/E)	0.00	0.00	947.07	465.39	375.56	410.47	932.43	584.00	733.00	938.21
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.11%	0.21%	0.27%	0.24%	0.11%	0.17%	0.14%	0.11%
Enterprise Value to Invested Capital (EV/IC)	69.88	49.81	53.91	49.77	41.28	46.60	47.47	32.26	38.53	44.43
Enterprise Value to Revenue (EV/Rev)	19.54	14.53	15.28	16.00	13.15	14.17	13.00	11.61	12.45	13.07
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	213.13	159.72	129.25	124.11	157.52	123.54	137.22	148.98
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	549.56	290.43	247.22	251.19	582.96	369.46	446.92	462.54
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	629.79	260.97	227.90	256.83	557.01	464.07	555.14	807.88
Enterprise Value to Operating Cash Flow (EV/OCF)	3,364.62	154.33	125.23	117.19	83.45	96.45	89.97	79.40	76.92	75.97
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	3,537.81	0.00	5,805.86	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.03	0.00	0.11	0.17	0.14	0.00	0.14	0.16	0.14
Long-Term Debt to Equity	0.00	0.03	0.00	0.11	0.17	0.14	0.00	0.14	0.16	0.14
Financial Leverage	-0.84	-0.62	-0.57	-0.44	-0.47	-0.46	-0.48	-0.26	-0.31	-0.37
Leverage Ratio	0.37	1.14	1.16	1.19	1.23	1.29	1.28	1.32	1.40	1.42
Compound Leverage Factor	0.37	1.74	1.28	1.94	1.31	1.68	0.94	1.51	1.68	1.82
Debt to Total Capital	0.00%	2.78%	0.00%	10.03%	14.16%	12.61%	0.00%	12.53%	13.64%	12.51%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	2.78%	0.00%	10.03%	14.16%	12.61%	0.00%	12.53%	13.64%	12.51%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	40.75%	36.12%	35.75%	30.03%	26.41%	26.86%	29.74%	24.57%	23.57%	23.13%
Common Equity to Total Capital	59.25%	61.10%	64.25%	59.94%	59.43%	60.53%	70.26%	62.91%	62.78%	64.36%
Debt to EBITDA	0.00	-0.47	0.00	0.49	0.70	0.56	0.00	0.72	0.86	0.81
Net Debt to EBITDA	0.00	9.56	0.00	-1.20	-1.14	-1.23	0.00	-1.22	-1.87	-2.28
Long-Term Debt to EBITDA	0.00	-0.47	0.00	0.49	0.70	0.56	0.00	0.72	0.86	0.81
Debt to NOPAT	0.00	-0.35	0.00	0.80	1.24	1.16	0.00	2.72	3.47	4.37
Net Debt to NOPAT	0.00	7.11	0.00	-1.97	-2.01	-2.54	0.00	-4.59	-7.56	-12.34
Long-Term Debt to NOPAT	0.00	-0.35	0.00	0.80	1.24	1.16	0.00	2.72	3.47	4.37
Altman Z-Score	134.69	65.05	65.10	71.52	46.58	47.10	50.16	42.90	38.01	36.69
Noncontrolling Interest Sharing Ratio	86.26%	40.11%	39.46%	37.66%	36.60%	34.41%	33.02%	30.45%	28.80%	28.32%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.01	5.57	6.32	4.33	3.79	3.44	4.07	4.15	3.62	3.42
Quick Ratio	7.72	5.09	5.76	3.85	3.45	3.14	3.67	3.81	3.41	3.16
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-7.64	-9.89	0.27	-7.22	-12	-8.32	-5.96	-13	-7.32	-6.13
Operating Cash Flow to CapEx	850.54%	430.76%	36.24%	271.20%	464.37%	286.97%	55.79%	270.29%	582.41%	363.24%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	-150.32	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	155.21	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	121.78	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.72	1.31	1.39	1.60	1.55	1.50	1.56	1.76	1.65	1.60
Accounts Receivable Turnover	5.90	6.82	6.58	6.06	6.26	6.47	6.57	6.40	6.84	6.71
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	10.15	10.44	9.85	9.72	10.05	10.24	10.17	10.13	10.10	10.27
Accounts Payable Turnover	25.17	22.36	39.87	60.42	43.79	29.58	26.00	73.95	50.95	42.14
Days Sales Outstanding (DSO)	61.82	53.50	55.46	60.26	58.30	56.38	55.56	57.01	53.33	54.36
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	14.50	16.32	9.15	6.04	8.33	12.34	14.04	4.94	7.16	8.66
Cash Conversion Cycle (CCC)	47.31	37.18	46.31	54.22	49.96	44.05	41.52	52.08	46.17	45.70
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	40	44	45	53	54	53	50	68	63	59
Invested Capital Turnover	4.11	3.91	3.70	3.41	3.61	3.60	3.85	3.13	3.34	3.59
Increase / (Decrease) in Invested Capital	10	11	4.05	9.28	14	9.20	5.19	15	9.36	6.24
Enterprise Value (EV)	2,769	2,185	2,402	2,614	2,217	2,472	2,361	2,186	2,430	2,635
Market Capitalization	2,791	2,206	2,421	2,609	2,214	2,473	2,369	2,183	2,437	2,649
Book Value per Share	$0.27	$0.29	$0.28	$0.21	$0.21	$0.21	$0.23	$0.25	$0.27	$0.28
Tangible Book Value per Share	$0.27	$0.29	$0.28	$0.21	$0.21	$0.21	$0.23	$0.25	$0.27	$0.28
Total Capital	103	106	99	80	85	89	83	102	111	114
Total Debt	0.00	2.96	0.00	8.05	12	11	0.00	13	15	14
Total Long-Term Debt	0.00	2.96	0.00	8.05	12	11	0.00	13	15	14
Net Debt	-64	-60	-55	-20	-20	-24	-33	-22	-33	-40
Capital Expenditures (CapEx)	0.92	1.75	2.55	2.22	2.61	2.30	2.75	2.71	2.78	2.66
Debt-free, Cash-free Net Working Capital (DFCFNWC)	20	17	18	18	14	14	21	22	14	12
Debt-free Net Working Capital (DFNWC)	84	79	73	46	46	50	54	56	62	66
Net Working Capital (NWC)	84	79	73	46	46	50	54	56	62	66
Net Nonoperating Expense (NNE)	0.05	0.11	-0.38	1.06	-0.30	-0.02	-0.02	-0.21	0.08	-0.06
Net Nonoperating Obligations (NNO)	-64	-60	-55	-20	-20	-24	-33	-22	-33	-40
Total Depreciation and Amortization (D&A)	1.71	1.70	1.87	2.09	2.53	3.59	2.73	2.93	3.02	3.31
Debt-free, Cash-free Net Working Capital to Revenue	14.47%	11.23%	11.67%	11.08%	8.32%	7.99%	11.36%	11.60%	6.95%	5.81%
Debt-free Net Working Capital to Revenue	59.31%	52.83%	46.41%	28.08%	27.09%	28.39%	29.47%	29.89%	31.70%	32.83%
Net Working Capital to Revenue	59.31%	52.83%	46.41%	28.08%	27.09%	28.39%	29.47%	29.89%	31.70%	32.83%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.02	$0.01	$0.04	$0.01	$0.02	$0.00	($0.01)	$0.02	$0.02	$0.00
Adjusted Weighted Average Basic Shares Outstanding	85.16M	85.39M	88.86M	88.31M	87.74M	88.20M	89.51M	91.48M	92.90M	92.05M
Adjusted Diluted Earnings per Share	$0.02	$0.01	$0.04	$0.01	$0.02	$0.00	($0.01)	$0.02	$0.02	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	131.76M	85.39M	132.35M	129.86M	127.84M	129.43M	89.51M	128.85M	128.98M	129.55M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	228.11M	230.54M	232.57M	246.86M	254.96M	256.14M	256.22M	256.82M	257.14M	258.00M
Normalized Net Operating Profit after Tax (NOPAT)	2.65	0.90	4.31	2.06	2.36	1.49	-0.78	2.34	2.04	1.11
Normalized NOPAT Margin	6.76%	2.21%	10.53%	4.82%	5.33%	3.21%	-1.62%	4.72%	3.99%	2.09%
Pre Tax Income Margin	7.37%	2.98%	12.42%	2.78%	6.83%	4.69%	-1.83%	5.96%	5.59%	4.64%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	36.59	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	30.30	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	3.17	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-3.13	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.66%	2.54%	2.93%	3.47%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.66%	2.54%	2.93%	3.47%

Frequently Asked Questions About Enfusion's Financials

When does Enfusion's financial year end?

According to the most recent income statement we have on file, Enfusion's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Enfusion's net income changed over the last 5 years?

Enfusion's net income appears to be on a downward trend, with a most recent value of $3.92 million in 2024, falling from $12.66 million in 2019. The previous period was $9.25 million in 2023. Find out what analysts predict for Enfusion in the coming months.

What is Enfusion's operating income?

Enfusion's total operating income in 2024 was $6.16 million, based on the following breakdown:

Total Gross Profit: $136.74 million
Total Operating Expenses: $130.58 million

How has Enfusion revenue changed over the last 5 years?

Over the last 5 years, Enfusion's total revenue changed from $59.03 million in 2019 to $201.61 million in 2024, a change of 241.6%.

How much debt does Enfusion have?

Enfusion's total liabilities were at $43.72 million at the end of 2024, a 38.8% increase from 2023, and a 59.2% decrease since 2020.

How much cash does Enfusion have?

In the past 4 years, Enfusion's cash and equivalents has ranged from $13.94 million in 2020 to $64.37 million in 2021, and is currently $54.48 million as of their latest financial filing in 2024.

How has Enfusion's book value per share changed over the last 5 years?

Over the last 5 years, Enfusion's book value per share changed from 0.00 in 2019 to 0.28 in 2024, a change of 28.5%.

Related Companies

This page (NYSE:ENFN) was last updated on 5/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enfusion (ENFN) Financials

Frequently Asked Questions About Enfusion's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enfusion (ENFN) Financials

Annual Income Statements for Enfusion

Quarterly Income Statements for Enfusion

Annual Cash Flow Statements for Enfusion

Quarterly Cash Flow Statements for Enfusion

Annual Balance Sheets for Enfusion

Quarterly Balance Sheets for Enfusion

Annual Metrics and Ratios for Enfusion

Quarterly Metrics and Ratios for Enfusion

Frequently Asked Questions About Enfusion's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools